{
    "2019-12-24": [
        [
            {
                "time": "",
                "original_text": "【中银医药】博雅生物收购资产点评：拟并入疫苗优质资产，罗益未来三年复合增速25%",
                "features": {
                    "keywords": [
                        "博雅生物",
                        "收购",
                        "疫苗",
                        "优质资产",
                        "罗益",
                        "复合增速",
                        "25%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}